Shopping Cart
Remove All
Your shopping cart is currently empty
R 59-022 (DKGI-I) is a diacylglycerol kinase (DGK) inhibitor and a 5-HT Receptor antagonist that blocks filovirus internalization in host cells. R 59-022 activates protein kinase C (PKC), inhibits intestinal smooth muscle contractility, and enhances O2- production induced by 1-oleoyl-2-acetylglycerol.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $32 | - | In Stock | |
| 5 mg | $72 | - | In Stock | |
| 10 mg | $128 | - | In Stock | |
| 25 mg | $298 | - | In Stock | |
| 50 mg | $497 | - | In Stock | |
| 100 mg | $815 | - | In Stock | |
| 200 mg | $1,080 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $73 | - | In Stock |
| Description | R 59-022 (DKGI-I) is a diacylglycerol kinase (DGK) inhibitor and a 5-HT Receptor antagonist that blocks filovirus internalization in host cells. R 59-022 activates protein kinase C (PKC), inhibits intestinal smooth muscle contractility, and enhances O2- production induced by 1-oleoyl-2-acetylglycerol. |
| Targets&IC50 | EBOV GP:~2 µM, DGK:2.8 μM |
| In vitro | Vero cells were treated with increasing concentrations of R 59-022 and exposed for 4 hours to MLV pseudotypes encoding LacZ and bearing EBOV GP or VSV-G in the presence of the drug. R 59-022 blocked an entry step specific to EBOV GP. Vero cells were treated with increasing concentrations of R 59-022 and exposed to VLPs bearing EBOV GP or VSV G in the presence of the drug for 3 h. By CCF2-AM staining and flow cytometry analysis, R 59-022 dose-dependent decrease in entry by the VLPs harboring the EBOV GP , IC50: ~2 µM. [5] |
| Synonyms | DKGI-I, Diacylglycerol kinase inhibitor I |
| Molecular Weight | 459.58 |
| Formula | C27H26FN3OS |
| Cas No. | 93076-89-2 |
| Smiles | O=C1C(=C(N=C2SC=CN21)C)CCN3CCC(=C(C=4C=CC=CC4)C5=CC=C(F)C=C5)CC3 |
| Relative Density. | 1.26g/cm3 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50 mg/mL (108.79 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.35 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.